---
title: "Goldman Sachs: The rise of the \"silver-haired group\" drives growth in high-end out-of-pocket treatment projects, focusing on the main stocks that benefit from this trend"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250904348.md"
description: "Goldman Sachs released a research report indicating that between 2024 and 2035, the healthcare spending of individuals aged 50 and above with a net worth exceeding 3 million RMB will significantly increase, with a compound annual growth rate of 14%/19%/9% (baseline/optimistic/pessimistic scenarios). The out-of-pocket medical expenses of this group will drive the growth of high-end treatment projects, particularly high-end dental implants and cataract surgeries. Recommended beneficiary stocks by Goldman Sachs include Aier, IM Motors, and Bright Eye Hospital Group"
datetime: "2025-07-31T03:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250904348.md)
  - [en](https://longbridge.com/en/news/250904348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250904348.md)
generator: "portal-rs"
---

# Goldman Sachs: The rise of the "silver-haired group" drives growth in high-end out-of-pocket treatment projects, focusing on the main stocks that benefit from this trend

According to the Zhitong Finance APP, Goldman Sachs released a research report stating that certain medical health services and treatment projects (such as high-end dental implants, cataract surgeries, and specific vaccines), which are not covered by the national health insurance or currently not affected by centralized drug procurement, can effectively continue to absorb the growing out-of-pocket medical expenses of the "silver-haired group" (aged 50 and above). Goldman Sachs specifically listed the main stocks most likely to benefit from the growth of high-end out-of-pocket treatment projects—upgrading Aier (300015.SZ) and Zhifei Biological (300122.SZ) to "Buy" ratings, giving Bright Eye Hospital Group (301239.SZ) and Straumann (SAUHY.US) "Buy" ratings, and raising the rating of SyntheMed (600763.SH) to "Neutral."

Goldman Sachs focuses on the "silver-haired group," which has strong "RMB" consumption capability (net assets exceeding 3 million RMB), and provided an independent estimate of the total addressable market (TAM), which is expected to grow from 221 billion RMB (31 billion USD) in 2024 to 963 billion RMB (135 billion USD) during the period from 2024 to 2035, with a compound annual growth rate of 14.3%. In contrast, the compound annual growth rates of medical health expenditures for the broader population aged 50 and above/overall population are 4.7%/5.3%, respectively. In 2024, this group, although only accounting for 3% of the total population aged 50 and above, contributes 5% of the medical health expenditures of this group. Goldman Sachs expects this proportion to increase to 13% (accounting for 5% of the population aged 50 and above) by 2035. Goldman Sachs assumes that during the period from 2024 to 2035, the compound annual growth rates of medical health expenditures for those aged 50 and above with net assets exceeding 3 million RMB will be 14%/19%/9% under baseline/optimistic/pessimistic scenarios

### Related Stocks

- [300015.CN](https://longbridge.com/en/quote/300015.CN.md)
- [301239.CN](https://longbridge.com/en/quote/301239.CN.md)

## Related News & Research

- [ETF Savings Plans Boom in Switzerland – But Not Because of AI](https://longbridge.com/en/news/296473012.md)
- [“How a Super El Niño Could Reshape Commodity Markets”](https://longbridge.com/en/news/296711482.md)
- [Patty Murray Rips Truth Social Play: ‘There Is No Get-Rich-Quick Scheme Trump Won’t Try’](https://longbridge.com/en/news/296346705.md)
- [Trump accuses Canada of charging tariffs on farmers for years](https://longbridge.com/en/news/296702652.md)
- [Oil edges higher as Iranian attacks on ships in Strait of Hormuz without U.S. response rise](https://longbridge.com/en/news/296280231.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**